Drawing on advances in genomics, proteomics and next-generation sequencing, SMi’s 6th annual Biomarkers Summit brings you the latest developments in this exciting field. From compound screening and toxicity testing to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development. You cannot afford to miss this event

Reasons to attend this exciting event include:

• Accelerate companion diagnostics development for therapeutic indications
• Validate and deliver biomarkers for patient selection during clinical trials
• Implement sub-grouping in patient segmentation studies
• Utilise revised FDA regulatory guidelines to aid product development
• Optimise reimbursement strategies for diagnostics
• Maximise biomarker identification using epigenetic and metabolomic insights

Key speakers include:

• Adam Platt, Diagnostic Development Director, AstraZeneca
• Andrew Warren, Director, PK/PD/Immunogenicity Bioanalysis, Novartis Pharma
• Christopher Foley, Clinical Imaging Manager, GlaxoSmithKline
• Graham Bell, Lead Technologist, Stratified Medicine, Technology Strategy Board
• Mirella Lazarov, Senior Director Biology, Head of Biomarkers, Gilead Sciences
• Nicholas Buss, Toxicology Project Leader, MedImmune
• Nick Crabb, Associate Director - Diagnostics Assessment Programme, National Institute for Health and Clinical Excellence

Book by 28th September 2012 to receive a £300 discount